
Senseonics Holdings (SENS) Stock Forecast & Price Target
Senseonics Holdings (SENS) Analyst Ratings
Bulls say
Senseonics Holdings Inc. has demonstrated significant revenue growth potential, reporting $8.3 million in revenue for the fourth quarter of 2024, contributing to a total of $22.5 million for fiscal year 2024. The approval and launch of the Eversense 365 continuous glucose monitor drove a remarkable 56% increase in the patient base, reaching approximately 6,000 global patients, which underscores the strong market acceptance and potential for patient acquisition. Additionally, early feedback from patients and clinicians has been overwhelmingly positive, with lead generation exceeding expectations by over 200% in the month following the product's approval, suggesting a promising trajectory for sustained revenue growth moving into 2025.
Bears say
Senseonics Holdings, Inc. reported a net loss of $15.5 million in 4Q24, an improvement from a $24.0 million loss in 3Q24, but still exceeds earnings forecasts, highlighting continued operational challenges. The company's business model faces significant risks, including stringent regulatory requirements for clinical studies, reliance on the success of its global commercialization partner, Ascensia Diabetes Care, and potential intellectual property issues that could hinder competitive advantages. Furthermore, concerns over market conditions impacting fundraising efforts and the possibility of poor stock performance leading to failure to meet Nasdaq listing requirements contribute to an unfavorable outlook for the company's financial stability.
This aggregate rating is based on analysts' research of Senseonics Holdings and is not a guaranteed prediction by Public.com or investment advice.
Senseonics Holdings (SENS) Analyst Forecast & Price Prediction
Start investing in Senseonics Holdings (SENS)
Order type
Buy in
Order amount
Est. shares
0 shares